



Substitute for form 1449A/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	09/786,867		
		<b>Filing Date</b>	March 12, 2001		
		<b>First Named Inventor</b>	MOROZ et al.		
		<b>Group Art Unit</b>			
		<b>Examiner Name</b>			
<b>Sheet</b>	1	<b>of</b>	3	<b>Attorney Docket Number</b>	MOROZ=3

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant/Inventor of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	4, 882,270		MOROZ	11-21-1989	
	AB	4,954,434		MOROZ	09-04-1990	
	AC	5,120,640		MOROZ et al.	06-09-1992	
	AD	5,283,177		MOROZ et al.	02-01-1994	
	AE	5,571,678		MOROZ et al.	11-05-1996	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number			Name of Patentee or Applicant/Inventor of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>5</sup> (if known)				
	AF	EP	0 426 458 A2		OKABE	05-08-1991		
	AG	PCT	WO 89/09936		MOROZ	10-19-1989		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AH	Abstract - XP-002131126 - ANDERSON et al. "Sequence and organization of the human mitochondrial genome", <u>Nature</u> , 290:457-465 (1981)	
	AI	Abstract - XP-002131125 - ZH LIFE TECHNOLOGY KENKYUSHO "Human monocyte growth factor", page 1, line 19-25 (1995)	
	AJ	Abstract of Japan - MANABU "Recombined growth factor for human monocyte, and DNA sequence coding the same" (1995)	
	AK	XP-000877132 - FISCH et al., "Placental isoferitin as a marker of early abortion in pregnancies induced by <i>in vitro</i> fertilization", <u>Piacenta</u> , 17:247-251 (1996)	
	AL	XP-000876880 - ROSEN "Placental isoferitin-associated p43 in pregnancy and breast cancer minireview", <u>Neoplasma</u> , 43:357-362 (1996)	

Examiner Signature	Date Considered
-----------------------	--------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
Application Number		09/786,867	
Filing Date		March 12, 2001	
First Named Inventor		MOROZ et al.	
Group Art Unit			
Examiner Name			
Attorney Docket Number		MOROZ=3	

AM	XP-000877134 – "Placental isoferitin: a new biomarker from conception to delivery", <u>British Journal of Obstetrics and Gynaecology</u> , 103:301-305 (1996)	
AN	XP-000876882 – YANIV et al., "p43, a new placental isoferitin subunit, is a growth factor for granulocyte-monocyte progenitor cells", page 272	
AM	XP-002131123 – MOROZ et al., "T-cell mitogenesis stimulates the synthesis of a mRNA species coding for a 43-kDa peptide reactive with CM-H-9, a monoclonal antibody specific for placental isoferitin", <u>Proc. Natl. Acad. Sci. USA</u> , 86:3282-3285 (1989)	
AO	XP-000876978 – GARTY et al., "High serum levels of placental isoferitin p43 component in down syndrome", <u>Human Sciences Press, Inc.</u> , 39-41 (1998)	
AP	XP-000876881- HIGGY et al., "Differential expression of human ferritin H chain gene in immortal human breast epithelial MCF-10F cells", <u>Molecular Carcinogenesis</u> , 20:332-339 (1997)	
AQ	XP-000876843 – BOYD et al., "Structural and functional relationships of human ferritin H and L chains deduced from cDNA clones", <u>The Journal of Biological Chemistry</u> , 260:11755-11761 (1985)	
AR	FERGUSON et al., "Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen", <u>Journal of Clinical Oncology</u> , 10:1057-1065 (1992)	
AS	WERNER et al., "Clinical utility and validation of emerging biochemical markers for mammary adenocarcinoma", <u>Clinical Chemistry</u> , 39:11(B)2386-2396 (1993)	
AT	JONES et al., "An immunoradiometric assay for the acidic ferritin of human heart: application to human tissues, cells and serum", <u>Clinica Chimica Acta</u> , 85:81-88 (1978)	
AU	GIANNOULIS et al., "Diagnostic value of serum ferritin in primary hepatocellular carcinoma", <u>Digestion</u> , 30:236-241 (1984)	
AV	FINE et al., "Ferritinaemia in cancer", <u>Nature</u> , 265:755-756 (1977)	
AW	COVELL et al., "Isoferritins in plasma", 49-65 (1984)	
AX	DRYSDALE "Ferritin phenotypes: structure and metabolism", 41-67	
AY	BROWN et al., "Characterization and localization of human placental ferritin", 182:763-769 (1979)	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of 3

**Complete if Known**

Application Number	09/786,867
Filing Date	March 12, 2001
First Named Inventor	MOROZ et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	MOROZ=3

AZ	PARHAMI-SEREN et al., "A unique subunit structure of human placenta ferritin identified by the use of monoclonal antibodies", <u>G. I. Pat. Clin.</u> , 1:17-23 (1986)
BA	AROSIO et al., "On ferritin heterogeneity further evidence for heteropolymers", <u>The Journal of biological Chemistry</u> , 253:4451-4458 (1978)
BB	DRYSDALE et al., "Carcinofetal human isoferritins in placenta and HeLa cells", <u>Cancer Research</u> , 34:3352-3354 (1974)
BC	MATZNER et al., "Serum ferritin in hematologic malignancies", <u>American Journal of Hematology</u> , 9:13-22 (1980)
BD	BEZWODA et al., "Serum ferritin and Hodgkin's disease", <u>Scand J Haematol.</u> , 35:505-510 (1985)
BE	CRAGG et al., "Isoferritins in acute leukaemia", <u>Br. J. Cancer</u> , 35:635-642 (1977)
BF	HALLIDAY et al., "Isoferritin composition of tissues and serum in human cancer", <u>Cancer Research</u> , 36:4486-4490 (1976)
BG	JONES et al., "Serum ferritin in patients with cancer: determinatin with antibodies to HeLa cell and spleen ferritin", <u>Clinica Chimica Acta</u> , 106:203-214 (1980)
BH	DALY et al., "Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen", <u>Journal of Clinical Oncology</u> , 10:1057-1065 (1992)
BI	DEMERS et al., "CA-549: A new tumor marker for patients with advanced breast cancer", <u>Journal of Clinical Laboratory Analysis</u> , 2:168-173 (1988)
BJ	DNISTRIAN et al., "Evaluation of CA M26, CA M29, CA 15-3 and CEA and circulating tumor markers in breast cancer patients", <u>Tumor Biol.</u> , 12:82-90 (1991)

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.